Skip to content
drillr.ai
Sign up

ABBV

AbbVie Inc.

NYSE · Healthcare · Drug Manufacturers - General · US

$263.78
−0.09%
Ask drillr

  • Sep 18, 2026, 12:30 UTC

    AbbVie presented new real-world data supporting the effectiveness of VRAYLAR (cariprazine) in adults with major depressive disorder and bipolar I depression at Psych Congress 2026 in New Orleans.

    Source:

  • Sep 17, 2026, 13:45 UTC

    Crohn's and Colitis Canada and AbbVie Canada announced the 2026 recipients of the AbbVie IBD Scholarship Program, awarding fifteen students across Canada $5,000 each.

    Source:

  • Sep 17, 2026, 12:00 UTC

    Allergan Aesthetics, an AbbVie company, announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow dermabrasion treatments in individuals taking medical weight loss medications, presented at the 2026 Science of Skin Summit.

    Source:

  • Sep 15, 2026, 12:00 UTC

    Allergan Aesthetics announced it will advance scientific dialogue on skin longevity, aging biology and exosome science at the 2026 Science of Skin Summit, including a featured SkinMedica R&D panel introducing the FACTS Principles.

    Source:

  • Sep 14, 2026, 22:45 UTC

    AbbVie (ABBV) shares rose 1.78% to settle at $261.7 on the latest trading day.

    Source:

  • Sep 11, 2026, 05:50 UTC

    Allergan Aesthetics received approval from China's National Medical Products Administration for the infraorbital hollow indication of its hyaluronic acid product Juvederm Volbella (cross-linked sodium hyaluronate gel with lidocaine).

    Source:

  • Sep 10, 2026, 18:17 UTC

    AbbVie Inc.'s board of directors declared a quarterly cash dividend of $1.73 per share.

    Source:

  • Sep 10, 2026, 12:55 UTC

    AbbVie announced positive Phase III study results for atogepant in the treatment of menstrual migraine, reinforcing its leadership in the migraine field.

    Source:

  • Sep 4, 2026, 15:53 UTC

    AbbVie announced that its drug etentamig met key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.

    Source:

  • Sep 3, 2026, 13:24 UTC

    AbbVie completed its $11 billion acquisition of Apogee Therapeutics.

    Source:

  • Sep 3, 2026, 13:15 UTC

    AbbVie announced that its CERVINO Phase 3 trial met dual primary endpoints, with full results to be presented from September 23 to 26.

    Source:

  • Sep 1, 2026, 12:05 UTC

    Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and HA5 Hydra Collagen Facial Mist as new regenerative skincare products in Irvine, California, on September 1, 2026.

    Source:

  • Aug 28, 2026, 00:18 UTC

    China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

    Source:

  • Aug 27, 2026, 06:00 UTC

    AbbVie submitted a regulatory application to the European Medicines Agency seeking approval for SKYRIZI (risankizumab) subcutaneous induction for adults with moderately to severely active Crohn's disease, supported by data from the Phase 3 AFFIRM study.

    Source:

  • Aug 25, 2026, 15:45 UTC

    Richard Gonzalez, former CEO of AbbVie, listed his Trump Tower condo for sale at $3.9 million.

    Source:

  • Aug 25, 2026, 08:09 UTC

    Donaldson Capital Management LLC increased its stake in AbbVie Inc. by 0.7% during the quarter, acquiring 3,553 additional shares, bringing its total holdings to 485,608 shares valued at $122.20 million.

    Source:

  • Aug 25, 2026, 08:09 UTC

    Convergence Financial LLC increased its stake in AbbVie Inc. by 91.7% during the quarter, acquiring an additional 2,713 shares to hold 5,670 shares, as disclosed in an SEC filing.

    Source:

  • Aug 24, 2026, 00:00 UTC

    Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.

  • Aug 23, 2026, 08:41 UTC

    Gateway Wealth Partners LLC reduced its stake in AbbVie Inc. by 40.8% during the second quarter, selling 11,835 shares and retaining 17,158 shares, as disclosed in a recent SEC filing.

    Source:

  • Aug 22, 2026, 09:45 UTC

    AbbVie EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on August 14th.

    Source:

  • Aug 21, 2026, 11:48 UTC

    AbbVie presented clinical data from its lung cancer research programs at the 2026 World Conference on Lung Cancer, including Phase 1b results for ABBV-1480 and a Phase 1b/2 study for telisotuzumab adizutecan.

    Source:

  • Aug 21, 2026, 11:30 UTC

    AbbVie announced a modified Dutch auction tender offer to repurchase up to $230 million of its common stock.

    Source:

  • Aug 19, 2026, 19:38 UTC

    Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.

    Source:

  • Aug 16, 2026, 13:57 UTC

    Zelgen Biopharmaceuticals reached a BD collaboration with AbbVie on ZG006, recognizing 662 million yuan in technology licensing revenue, with both parties accelerating global development.

    Source:

  • Aug 4, 2026, 13:09 UTC

    AbbVie Inc. is seeking to raise at least $8 billion through an investment-grade bond offering to fund part of its acquisition of Apogee Therapeutics Inc.

    Source:

  • Jul 31, 2026, 11:47 UTC

    AbbVie reported second-quarter 2026 financial results with diluted EPS of $2.03 on a GAAP basis and adjusted diluted EPS of $3.65, and net revenues of $16.990 billion, an increase of 10.2 percent on a reported basis.

    Source:

  • Jul 9, 2026, 14:01 UTC

    West Pharmaceutical Services completed the sale of its SmartDose 3.5mL platform to AbbVie.

    Source:
Page 1Next →